Friday, 19 Jul 2019

You are here

High 14-3-3η Levels Have Predictive Value in Early Inflammatory Arthritis

14-3-3η is a new serum assay that has utility in diagnosing and treating patients with rheumatoid arthritis (RA) and early inflammatory arthritis (EIA).  However, the role of this test in patients with RA and EIA is being defined by current research.  

14-3-3η is not known to have a pathogenic role in RA, but has been shown to induce numerous proinflammatory mediators. Patients with elevated levels have a greater risk of evolving from arthralgia to chronic arthritis, and may have more severe disease or more radiographic damage. Interestingly, 14-3-3η levels do not correlate with acute phase reactant levels (ESR, CRP) or disease activity scores, and weakly correlate with RF and CCP antibody levels. The 14-3-3η (also known as IdentRA in the USA and JOINTstat elsewhere) test costs between $60 and $130.

A recent study evaluated the prognostic potential of serum 14-3-3η protein levels in 331 EIA patients, half of whom had either RF or CCP antibodies. Higher levels were associated with lower odds of achieving SDAI remission and greater risk of radiographic damage. Decreases of 14-3-3η levels by at least 0.76 ng/ml and reversion to negative during follow-up was associated with less subsequent radiographic progression.

Higher levels of 14-3-3η (≥0.50 ng/ml) were correlated with poorer clinical and radiographic outcomes EIA patients.  Overall, 14-3-3η, CRP, age and other RA Abs (RF, CCP) represent independent predictors of subsequent joint damage.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Upadacitinib Superior to Adalimumab in Methotrexate Refractory RA

Upadacitinib, a JAK1-selective inhibitor, was studied head to head against adalimumab and placebo in rheumatoid arthritis after an inadequate response to methotrexate, and shown to be superior to ADA and PBO in ACR20 and DAS remission level responses.

CRP Utility in COPD Exacerbations

NEJM reports on the utility of C-reactive protein (CRP) testing in chronic obstructive pulmonary disease (COPD) patients, showing that CRP guided prescribing of antibiotics for exacerbations of COPD in primary care clinics resulted in a lower percentage of patients who reported antibiotic use.

EULAR 2019 - Day 1 Report

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Here are a few of the highlights from day 1 EULAR in Madrid, including another IL-23 inhibitor, BTK inhibition, abatacept in Sjogren's syndrome, don't repeat the ANA, and drug free remission in systemic JIA.

Borrelia burgdorferi Peptidoglycan Shedding Drives Lyme Arthritis

Research published in PNAS has shown that long after active Lyme infection in the joint, a peptidoglycan (PG) of the the spirochete Borrelia burgdorferi can be found in the joints of those with late-stage Lyme disease.

 

EULAR 2019 - Day 1 Report

Here are a few of the highlights from day 1 EULAR in Madrid.